JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
Bristol-Myers Squibb
Wake Forest University Health Sciences
Stanford University
Stanford University
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Atara Biotherapeutics
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Northwestern University
Roswell Park Cancer Institute
AbbVie
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
miRagen Therapeutics, Inc.
Mayo Clinic
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Mayo Clinic
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
University of Wisconsin, Madison
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
University of Chicago
City of Hope Medical Center
Case Comprehensive Cancer Center